Render Target: SSR
Render Timestamp: 2024-11-25T04:53:09.411Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-11-19 23:03:11.607
Product last modified at: 2024-11-23T09:00:11.565Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Vitronectin (F8D3L) Rabbit mAb #53507

Filter:
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Rabbit IgG
    Application Key:
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunohistochemistry (Paraffin) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Vitronectin (F8D3L) Rabbit mAb recognizes endogenous levels of total vitronectin protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu133 of human vitronectin protein.

    Background

    Vitronectin (VTN) is a multidomain adhesive glycoprotein synthesized mostly in the liver and secreted to blood plasma and extracellular matrix (ECM) (1,2). The protein has an N-terminal SMB fragment mediating binding to PAI-1 and UPAR, followed by an RGD region mediating its interaction with integrins, and C-terminal hemopexin-like domains mediating its interaction with various ECM components such as collagens, tenascins, and plasminogen (2,3). VTN has been implicated as a regulator of many diverse physiological processes, including coagulation, complement-dependent immune response, cell attachment and spreading, angiogenesis, hemostasis, and vascular remodeling (4-6). Increased VTN expression promotes cancer cell migration, adhesion, and metastasis in neuroblastoma, ovarian cancer, and breast cancer cells (7-9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.